111 related articles for article (PubMed ID: 18587707)
1. Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses.
Michałowska-Wender G; Wender M
Folia Neuropathol; 2008; 46(2):134-8. PubMed ID: 18587707
[TBL] [Abstract][Full Text] [Related]
2. CD95/Fas expression on peripheral blood T lymphocytes in patients with multiple sclerosis: effect of high-dose methylprednisolone therapy.
Petelin Z; Brinar V; Petravic D; Zurak N; Dubravcic K; Batinic D
Clin Neurol Neurosurg; 2004 Jun; 106(3):259-62. PubMed ID: 15177780
[TBL] [Abstract][Full Text] [Related]
3. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.
Martínez-Cáceres EM; Barrau MA; Brieva L; Espejo C; Barberà N; Montalban X
Clin Exp Immunol; 2002 Jan; 127(1):165-71. PubMed ID: 11882048
[TBL] [Abstract][Full Text] [Related]
4. Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.
Kraus J; Oschmann P; Engelhardt B; Bauer R; Schiel C; Kern A; Stolz E; Traupe A; Dorndorf W
Acta Neurol Scand; 2000 Feb; 101(2):135-9. PubMed ID: 10685862
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with relapsing-remitting multiple sclerosis.
Bilińska M; Frydecka I; Podemski R; Teodorowska R; Gruszka E
Med Sci Monit; 2001; 7(2):251-5. PubMed ID: 11257731
[TBL] [Abstract][Full Text] [Related]
6. The expression of integrins on activated T-cells in multiple sclerosis. Effect of intravenous methylprednisolone treatment.
Luján S; Masjuan J; Roldán E; Villar LM; González-Porqué P; Alvarez-Cermeño JC
Mult Scler; 1998 Jun; 4(3):239-42. PubMed ID: 9762681
[TBL] [Abstract][Full Text] [Related]
7. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Frequin ST; Lamers KJ; Borm GF; Barkhof F; Jongen PJ; Hommes OR
Acta Neurol Scand; 1993 Aug; 88(2):80-6. PubMed ID: 8213063
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid Therapy of Multiple Sclerosis Patients Induces Anti-inflammatory Polarization and Increased Chemotaxis of Monocytes.
Fischer HJ; Finck TLK; Pellkofer HL; Reichardt HM; Lühder F
Front Immunol; 2019; 10():1200. PubMed ID: 31191554
[TBL] [Abstract][Full Text] [Related]
10. The impact of multiple sclerosis relapse treatment on migration of effector T cells--Preliminary study.
Jatczak-Pawlik I; Książek-Winiarek D; Wojkowska D; Jóźwiak K; Jastrzębski K; Pietruczuk M; Głąbiński A
Neurol Neurochir Pol; 2016; 50(3):155-62. PubMed ID: 27154441
[TBL] [Abstract][Full Text] [Related]
11. CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis.
Kraus J; Oschmann P; Engelhardt B; Stolz E; Kuehne BS; Laske C; Schaefer C; Traupe H; Kaps M
Acta Neurol Scand; 2000 Nov; 102(5):326-32. PubMed ID: 11083511
[TBL] [Abstract][Full Text] [Related]
12. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.
Moreira MA; Tilbery CP; Monteiro LP; Teixeira MM; Teixeira AL
Acta Neurol Scand; 2006 Aug; 114(2):109-13. PubMed ID: 16867033
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse.
Mahad DJ; Lawry J; Howell SJ; Woodroofe MN
Mult Scler; 2003 Mar; 9(2):189-98. PubMed ID: 12708814
[TBL] [Abstract][Full Text] [Related]
14. New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids.
de Andrés C; Tejera-Alhambra M; Alonso B; Valor L; Teijeiro R; Ramos-Medina R; Mateos D; Faure F; Sánchez-Ramón S
J Neuroimmunol; 2014 May; 270(1-2):37-44. PubMed ID: 24662004
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression in B cells and T helper cells following high-dose glucocorticoid therapy for multiple sclerosis relapse.
Hecker M; Fitzner B; Koczan D; Klehmet J; Grothe M; Schwab M; Winkelmann A; Meister S; Dudesek A; Ludwig-Portugall I; Eulitz K; Zettl UK
Biomed Pharmacother; 2024 Jun; 175():116721. PubMed ID: 38749180
[TBL] [Abstract][Full Text] [Related]
16. Intravenous cyclophosphamide combined with methylprednisolone in the treatment of severe refractory rheumatoid arthritis: the effect on lymphocytes.
Lacki JK; Leszczynski P; Mackiewicz SH
J Investig Allergol Clin Immunol; 1996; 6(4):232-6. PubMed ID: 8844499
[TBL] [Abstract][Full Text] [Related]
17. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis.
Grove RA; Shackelford S; Sopper S; Pirruccello S; Horrigan J; Havrdova E; Gold M; Graff O
Eur J Neurol; 2013 Jul; 20(7):1032-42. PubMed ID: 23419064
[TBL] [Abstract][Full Text] [Related]
19. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.
Leussink VI; Jung S; Merschdorf U; Toyka KV; Gold R
Arch Neurol; 2001 Jan; 58(1):91-7. PubMed ID: 11176941
[TBL] [Abstract][Full Text] [Related]
20. [Immunogenetic cytokine restriction in multiple sclerosis].
Odinak MM; Bisaga GN; kalinina NM; Akimov SB; Davydova NI
Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(9):39-44. PubMed ID: 11586702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
